A PHASE I DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABLITY AND PHARMACOKINETICS OF AB-16B5 IN SUBJECTS WITH AN ADVANCED SOLID MALIGNANCY.
- Registry ID
- AB-16B5-101
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- ALETHIA BIOTHERAPEUTICS INC
- Start date
- 2015-05-04
- Last update
- 2015-03-16
Conditions
Related clinical trials
- A FIRST-IN-HUMAN PHASE I, NON-RANDOMIZED, OPEN-LABEL, MULTICENTER DOSE ESCALATION TRIAL OF BI 765049 AND BI 765049 + EZABENLIMAB ADMINISTERED BY REPEATED INTRAVENOUS INFUSIONS IN PATIENTS WITH MALIGNANT SOLID TUMORS EXPRESSING B7-H6
- AN OPEN-LABEL, MULTICENTER, MULTICOHORT, PHASE 2 STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS (EV-202)
- A PILOT STUDY OF ATEZOLIZUMAB (MPDL3280A) FOLLOWING ADOPTIVE CELL TRANSFER IN ACTIVE HEMATOLOGIC OR SOLID TUMOR MALIGNANCIES
- AN OPEN-LABEL, MULTI-CENTRE, SAFETY STUDY OF FIXED-DOSE DURVALUMAB + TREMELIMUMAB COMBINATION THERAPY OR DURVALUMAB MONOTHERAPY IN ADVANCED SOLID MALIGNANCIES (STRONG) -- CORE PROTOCOL
- A PHASE I/II MULTICENTER, OPEN-LABEL STUDY OF CLR457, ADMINISTERED ORALLY IN ADULT PATIENTS WITH ADVANCED SOLID MALIGNANCIES
- "A PHASE 1 STUDY OF THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF AGS-22M6E GIVEN AS MONOTHERAPY FOLLOWED BY EXPANSION COHORTS IN SUBJECTS WITH MALIGNANT SOLID TUMORS THAT EXPRESS NECTIN-4."
View on source registry